

Preferences for Receiving Clinical Trials Information of Asian, Native Hawaiian, and Pacific Islander Patients with Type 2 Diabetes Mellitus

PCR68



Sentell TL^{1,2}; Taira DA^{1,2}; Tengan K¹; Takata J¹; Porter C¹; Ranken MS¹; Suzuki M³; Hsieh J⁴; Lee CS⁴; Seto TB^{1,2}

¹The Queen's Medical Center, Honolulu, HI, USA; ²University of Hawai'i, Honolulu and Hilo, Hawai'i, USA; ³Office of New Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA; ⁴Office of Minority Health and Health Equity, Office of the Commissioner, US Food and Drug Administration, Silver Spring, MD, USA

INTRODUCTION

Asian (Filipino), Native Hawaiian, and Pacific Islander populations are often underrepresented in clinical trials.

OBJECTIVE

To identify how Native Hawaiian, Pacific Islander, Filipino, and White patients want to receive information on clinical trials.

METHODS

- In-person semi-structured interviews were conducted in English for a convenience sample of patients with type 2 diabetes mellitus, hospitalized in a large medical center in Hawaii.
- Interviews asked questions related to access, community engagement, and reducing trial burden.
- Rapid Qualitative Analysis was conducted to determine key takeaways for each subject area.

RESULTS

Table 1. Characteristics of Study Participants

	Native Hawaiian (n = 17)	Pacific Islander (n =16)	Filipino (n = 15)	White (n = 8)
Age (mean±SD)	58.6±12.6	54.9±15.6	60.7±9.3	71.0±8.2
Female (%)	17.6%	62.5%	40.0%	50.0%
Born in US (%)	100.0%	18.8%	53.3%	100.0%
Education (%)				
<High school	11.8%	20.0%	0.0%	0.0%
High school	58.8%	46.7%	53.3%	37.5%
College	29.4%	33.3%	46.7%	37.5%
Graduate school	0.0%	0.0%	0.0%	25.0%

86% of patients reported wanting to receive information about clinical trials for which they might be eligible

Figure 1. Preferences for Receiving Information Across All Groups




Figure 2. Native Hawaiian Patient Preferences for Receiving Information




Figure 3. Pacific Islander Patient Preferences for Receiving Information





Figure 4. Filipino Patient Preferences for Receiving Information



CONCLUSIONS

- Nearly 90% of patients wanted to receive clinical trial information.
- Most wanted the information from their physicians.
- Texts and physical mail were also preferred communication modes.

FUNDING

This project is supported by the Food and Drug Administration (FDA) Office of Minority Health and Health Equity of the U.S. Department of Health and Human Services (HHS) (10903 New Hampshire Ave; Silver Spring, MD 20993) as part of a financial assistance award [FAIN U01FD007974] totaling \$499,514 with 100 percent funded by FDA OMHHE/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.

CONTACT INFORMATION

Tetine Sentell, PhD, at tsentell@hawaii.edu